MX2022003982A - Metodos de tratamiento de enfermedades relacionadas con el receptor s1p1. - Google Patents
Metodos de tratamiento de enfermedades relacionadas con el receptor s1p1.Info
- Publication number
- MX2022003982A MX2022003982A MX2022003982A MX2022003982A MX2022003982A MX 2022003982 A MX2022003982 A MX 2022003982A MX 2022003982 A MX2022003982 A MX 2022003982A MX 2022003982 A MX2022003982 A MX 2022003982A MX 2022003982 A MX2022003982 A MX 2022003982A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- methods
- receptor
- conditions related
- treating conditions
- Prior art date
Links
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 3
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962909113P | 2019-10-01 | 2019-10-01 | |
| PCT/US2020/053642 WO2021067506A1 (en) | 2019-10-01 | 2020-09-30 | Methods of treating conditions related to the s1p1 receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022003982A true MX2022003982A (es) | 2022-07-12 |
Family
ID=75337529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022003982A MX2022003982A (es) | 2019-10-01 | 2020-09-30 | Metodos de tratamiento de enfermedades relacionadas con el receptor s1p1. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220347158A1 (https=) |
| EP (1) | EP4037678A4 (https=) |
| JP (1) | JP2022550458A (https=) |
| KR (1) | KR20220074913A (https=) |
| CN (2) | CN115038438A (https=) |
| AU (1) | AU2020360413A1 (https=) |
| BR (1) | BR112022005999A2 (https=) |
| CA (1) | CA3156182A1 (https=) |
| IL (1) | IL291654A (https=) |
| MX (1) | MX2022003982A (https=) |
| TW (1) | TW202114656A (https=) |
| WO (1) | WO2021067506A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240134360A (ko) | 2022-01-13 | 2024-09-09 | 아레나 파마슈티칼스, 인크. | 호르몬 치료와 조합되어 s1p1 수용체-연관된 장애를 치료하는 데 사용하기 위한 에트라시모드 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8580841B2 (en) * | 2008-07-23 | 2013-11-12 | Arena Pharmaceuticals, Inc. | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
| JP5856980B2 (ja) * | 2010-01-27 | 2016-02-10 | アリーナ ファーマシューティカルズ， インコーポレイテッド | （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス |
| PL3242666T3 (pl) * | 2015-01-06 | 2025-02-17 | Arena Pharmaceuticals, Inc. | Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1 |
| BR112017027656B1 (pt) * | 2015-06-22 | 2023-12-05 | Arena Pharmaceuticals, Inc. | Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo |
| MX2019009843A (es) * | 2017-02-16 | 2020-01-30 | Arena Pharm Inc | Compuestos y metodos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales. |
-
2020
- 2020-09-30 CN CN202080076189.6A patent/CN115038438A/zh active Pending
- 2020-09-30 BR BR112022005999A patent/BR112022005999A2/pt not_active Application Discontinuation
- 2020-09-30 WO PCT/US2020/053642 patent/WO2021067506A1/en not_active Ceased
- 2020-09-30 US US17/765,619 patent/US20220347158A1/en not_active Abandoned
- 2020-09-30 CN CN202411419528.2A patent/CN119280227A/zh active Pending
- 2020-09-30 JP JP2022520471A patent/JP2022550458A/ja active Pending
- 2020-09-30 AU AU2020360413A patent/AU2020360413A1/en active Pending
- 2020-09-30 CA CA3156182A patent/CA3156182A1/en active Pending
- 2020-09-30 EP EP20873256.0A patent/EP4037678A4/en not_active Withdrawn
- 2020-09-30 TW TW109134240A patent/TW202114656A/zh unknown
- 2020-09-30 MX MX2022003982A patent/MX2022003982A/es unknown
- 2020-09-30 KR KR1020227014194A patent/KR20220074913A/ko not_active Withdrawn
-
2022
- 2022-03-23 IL IL291654A patent/IL291654A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020360413A8 (en) | 2022-04-21 |
| WO2021067506A1 (en) | 2021-04-08 |
| IL291654A (en) | 2022-05-01 |
| BR112022005999A2 (pt) | 2022-07-12 |
| US20220347158A1 (en) | 2022-11-03 |
| TW202114656A (zh) | 2021-04-16 |
| CN119280227A (zh) | 2025-01-10 |
| KR20220074913A (ko) | 2022-06-03 |
| CN115038438A (zh) | 2022-09-09 |
| EP4037678A1 (en) | 2022-08-10 |
| EP4037678A4 (en) | 2023-11-29 |
| CA3156182A1 (en) | 2021-04-08 |
| JP2022550458A (ja) | 2022-12-01 |
| AU2020360413A1 (en) | 2022-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020013157A (es) | Métodos de tratamiento de afecciones relacionadas con el receptor s1p1. | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| MX2020013116A (es) | Sales y cristales novedosos. | |
| AR119158A1 (es) | Tratamientos de angioedema hereditario | |
| EA202191079A1 (ru) | Способы лечения синдрома ретта с применением фенфлурамина | |
| MX2017005299A (es) | Metodo de tratamiento de afecciones relacionadas con el receptor pgi2. | |
| MA52424B1 (fr) | Compositions pharmaceutiques comprenant du (2s)--((1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl)-1,4-oxazepane-2-carboxamide | |
| PE20150161A1 (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple | |
| MX2019009841A (es) | Compuestos y metodos para el tratamiento de la colangitis biliar primaria. | |
| MX376312B (es) | Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash | |
| CO2022005999A2 (es) | Inhibidores del factor d del complemento para administración oral | |
| AR090929A1 (es) | Identificacion de la respuesta de un paciente a la administracion del modulador del receptor de s1p | |
| NZ776354A (en) | Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| MX2022008342A (es) | Metodos para tratar afecciones relacionadas con el receptor de s1p1. | |
| PE20241327A1 (es) | Tratamiento de trastornos hepaticos con un agonista del thr-beta | |
| MX2022006083A (es) | Metodos para tratar afecciones relacionadas con el receptor s1p1. | |
| PY1944026A (es) | Ácido ascórbico y compuestos quinona en combinación con un agente antiparasitario para tratar enfermedades parasitarias | |
| MX2022003982A (es) | Metodos de tratamiento de enfermedades relacionadas con el receptor s1p1. | |
| ECSP19027578A (es) | Composición farmacéutica con antagonista del receptor de mineralocorticoides y su uso | |
| AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
| AR029666A1 (es) | Uso del (+) -alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinmetanol o su prodroga para la manufactura de un medicamento en el tratamiento de los sintomas de la demencia y de la psicosis inducida por dopamina | |
| MX2019000413A (es) | Inhibidores de triptofano 2,3-dioxigenasa. | |
| AR080048A1 (es) | Tratamiento del tumor del estroma gastrointestinal (gist) con masitinib | |
| RU2017126044A (ru) | Соединение тиотриазола и его применения при лечении паразитарных протозойных инфекций |